Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis

Objective We sought to determine if vitamin D status, a risk factor for multiple sclerosis, is associated with the rate of subsequent clinical relapses in pediatric‐onset multiple sclerosis. Methods This is a retrospective study of patients with pediatric‐onset multiple sclerosis or clinically isola...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Annals of neurology Ročník 67; číslo 5; s. 618 - 624
Hlavní autoři: Mowry, Ellen M., Krupp, Lauren B., Milazzo, Maria, Chabas, Dorothee, Strober, Jonathan B., Belman, Anita L., McDonald, Jamie C., Oksenberg, Jorge R., Bacchetti, Peter, Waubant, Emmanuelle
Médium: Journal Article
Jazyk:angličtina
Vydáno: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.05.2010
Wiley-Liss
Témata:
Adolescent
Biological and medical sciences
Calcifediol - blood
Child
Cohort Studies
Female
Humans
Male
Medical sciences
Multiple Sclerosis - blood
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Neurology
Pediatrics
Recurrence
Regression Analysis
Retrospective Studies
Risk Factors
Young Adult
Human
Pediatrics
Nervous system diseases
Relapse
Multiple sclerosis
Vitamin D
Central nervous system disease
Child
Inflammatory disease
ISSN:0364-5134, 1531-8249, 1531-8249
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Objective We sought to determine if vitamin D status, a risk factor for multiple sclerosis, is associated with the rate of subsequent clinical relapses in pediatric‐onset multiple sclerosis. Methods This is a retrospective study of patients with pediatric‐onset multiple sclerosis or clinically isolated syndrome who were consecutively recruited into a prospective cohort at their clinical visit at the pediatric multiple sclerosis center of University of California, San Francisco or State University of New York at Stony Brook. Of 171 eligible patients, 134 (78%) with multiple sclerosis/clinically isolated syndrome were included in the cohort; a further 24 were excluded from this analysis due to lack of available serum (n = 7) or lack of follow‐up (n = 17). Serum 25‐hydroxyvitamin D3 levels were measured and were adjusted to reflect a deseasonalized value. The adjusted serum 25‐hydroxyvitamin D3 level was the primary predictor in a multivariate negative binomial regression model in which the main outcome measure was the number of subsequent relapses. Results Among the 110 subjects, the mean unadjusted 25‐hydroxyvitamin D3 level was 22 ± 9ng/ml. After adjustment for age, gender, race, ethnicity, disease duration, disease‐modifying therapy, and length of follow‐up, every 10ng/ml increase in the adjusted 25‐hydroxyvitamin D3 level was associated with a 34% decrease in the rate of subsequent relapses (incidence rate ratio, 0.66; 95% confidence interval, 0.46–0.95; p = 0.024). Interpretation Lower serum 25‐hydroxyvitamin D3 levels are associated with a substantially increased subsequent relapse rate in pediatric‐onset multiple sclerosis or clinically isolated syndrome, providing rationale for a randomized controlled trial of vitamin D supplementation. ANN NEUROL 2010;67:618–624
Bibliografie:National MS Society - No. A103210
istex:8F70F9CEBF917FB6DA4599AEE245B152D0B5968F
ark:/67375/WNG-6MP0B43N-Q
ArticleID:ANA21972
National Multiple Sclerosis Society Sylvia Lawry Fellowship Award
Donation from a patient's family
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0364-5134
1531-8249
1531-8249
DOI:10.1002/ana.21972